alpha-(苯氧基甲基)-4-(3-甲氧基苯基)-1-哌嗪乙醇 | 66307-55-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: alpha-(苯氧基甲基)-4-(3-甲氧基苯基)-1-哌嗪乙醇
• 英文名称: 1-[4-(3-methoxy-phenyl)-piperazin-1-yl]-3-phenoxy-propan-2-ol
• 英文别名: 4-(m-Methoxyphenyl)-alpha-phenoxymethyl-1-piperazineethanol；1-[4-(3-methoxyphenyl)piperazin-1-yl]-3-phenoxypropan-2-ol
• CAS: 66307-55-9
• 化学式: C₂₀H₂₆N₂O₃
• 分子量: 342.438
• InChiKey: GAEVZJMONMLEOR-UHFFFAOYSA-N

物化性质

• 熔点：
  95 °C
• 沸点：
  528.0±50.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF
  申请人：Exciva GmbH

  公开号：EP3618819A1

  公开（公告）日：2020-03-11
• [EN] TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF<br/>[FR] TARGETED DRUG RESCUE AVEC DE NOUVELLES COMPOSITIONS, ASSOCIATIONS ET PROCÉDÉS CORRESPONDANTS
  申请人：EXCIVA UG HAFTUNGSBESCHRAENKT

  公开号：WO2018204713A1

  公开（公告）日：2018-11-08

  Compounds of Formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of Formula I, or enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof, wherein the compound is double and/or triple agent or ligand for CYP2D6, 5-HT2A, and/or 5HT2C receptors, and/or acetylcholinesterase are provided.